Page 5 - Pearl Index News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pearl index. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pearl Index Today - Breaking & Trending Today

New Efficacy Data Reinforces NEXTSTELLIS® Benefits Across Patient Populations

New Efficacy Data Reinforces NEXTSTELLIS® Benefits Across Patient Populations
Results presented at the 2021 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting
News provided by
Share this article
Share this article
GREENVILLE, N.C., April 30, 2021 /PRNewswire/ Mayne Pharma announced today results from two studies showing treatment with NEXTSTELLIS® (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets) demonstrated contraceptive efficacy and excellent cycle control across subgroups, including age, body mass index (BMI)[1] and prior contraceptive use. NEXTSTELLIS is the first contraceptive pill containing E4, a new naturally occurring estrogen with a unique mechanism of action that offers potential advantages over other estrogens. The findings were presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting, held virtually in the U.S. from April 30 – Ma ....

United States , Mashonaland East , Mayne Pharma , Prnewswire Mayne Pharma , Estetrol Drospirenone , Karen Dombek , Mitchell Creinin , University Of California , Mayne Pharma Group , American College Of Obstetricians , Women Health , Annual Clinical , Scientific Meeting , Family Planning , Pearl Index , Subgroup Analysis , Pregnancy Prevention , Canadian Phase , Prescribing Information , Sensitive Malignancy , Full Prescribing Information , Mayne Pharma Group Limited , ஒன்றுபட்டது மாநிலங்களில் , மஷோனலண்ட் கிழக்கு , மேனே பார்மா , கரேன் தொம்பேக் ,

Pfizer, Myovant begin dosing in relugolix contraceptive study

Pfizer, Myovant begin dosing in relugolix contraceptive study
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

Juan Camilo Arjona Ferreira , Myovant Sciences , Pearl Index , முத்து குறியீட்டு ,

Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily

Date Time
Share
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily
SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 years
Contraceptive potential of relugolix combination tablet supported by prior Phase 1 study that demonstrated 100% ovulation inhibition
Data would support a potential indication of pregnancy prevention for women treated with relugolix combination tablet, if approved
BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in healthy women age ....

James Rusnak , Juan Camilo Arjona Ferreira , Pfizer Inc , Myovant Sciences Inc , Myovant Sciences , Drug Administration , Global Product Development At Pfizer , Chief Medical Officer , Pearl Index , Senior Vice President , Chief Development Officer , Internal Medicine , Global Product Development , New Drug Application , Health Care , ஜேம்ஸ் ருஸ்னக் , ஃபைசர் இன்க் , உலகளாவிய ப்ராடக்ட் வளர்ச்சி இல் ஃபைசர் , தலைமை மருத்துவ அதிகாரி , முத்து குறியீட்டு , மூத்தவர் துணை ப்ரெஸிடெஂட் , தலைமை வளர்ச்சி அதிகாரி , உள் மருந்து , உலகளாவிய ப்ராடக்ட் வளர்ச்சி , புதியது மருந்து விண்ணப்பம் , ஆரோக்கியம் பராமரிப்பு ,

Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating ...

Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating ...
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United States , Albert Liao , Bryan Crowe , Steve Danehy , James Rusnak , Chuck Triano , Juan Camilo Arjona Ferreira , Myovant Sciences Forward , Myovant Sciences , Global Product Development At Pfizer , Exchange Commission , Myovant Sciences Contacts , Pfizer Inc , Myovant Sciences Inc , Sumitomo Dainippon Pharma Co Ltd , Sumitovant Biopharma Ltd , Chief Medical Officer , Pearl Index , Senior Vice President , Chief Development Officer , Internal Medicine , Global Product Development , Sumitovant Biopharma , Breakthroughs That Change Patient Lives , Pfizer News , Private Securities Litigation Reform Act ,

Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal .
Myovant Sciences, Inc.February 11, 2021 GMT
ORGOVYX™ (relugolix) approved by the
U.S. Food and Drug Administration (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer; ORGOVYX launched in the U.S. in early January 2021
Announced collaboration with Pfizer in December 2020 to jointly develop and commercialize relugolix in oncology and relugolix combination tablet in women’s health in the U.S. and Canada ....

New York , United States , City Of , United Kingdom , Sumitomo Dainippon Pharma , David Marek , Albert Liao , Bryan Crowe , Endometriosis Special Interest Group , Dainippon Pharmaceutical Co Ltd , European Union , Virtual Congress , American Society For Reproductive Medicine , Canada The Co , European Commission , Drug Administration , Myovant Sciences , Gedeon Richter , Exchange Commission , Myovant Sciences Ltd , Corporate Communications , Myovant Sciences Inc , European Medicines Agency , Scientific Congress Prize Paper Session , Sumitomo Dainippon Pharma Co Ltd , Sumitomo Pharmaceuticals Co Ltd ,